Whooping cough and Parkinson's disease

International Journal of Epidemiology

Volumn 25, Issue 6, 1996, Pages 1301-1311

  De Pedro Cuesta, Jesus ^a,b   Gudmundsson, Gretar ^c   Abraira, Victor ^d,e   Gudmundsson, Gunnar ^c   Löve, Arthur ^f   Tulinius, Hrafn ^f   Veiga, Jorge ^a   Almazán, Javier ^a   Petersen, Ingolf J ^g  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f Hospital of Iceland   (Iceland)

^g Science and Culture   (Iceland)

Author keywords

Aetiology; Dopamine; Drug use; Epidemiology; Parkinson's disease; Pertussis

Indexed keywords

ADENYLATE CYCLASE; DOPAMINE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LEVODOPA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; HUMAN; ICELAND; INFANT; MAJOR CLINICAL STUDY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PERTUSSIS; PREVALENCE; PRIORITY JOURNAL; RAT; RISK;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HUMANS; ICELAND; INCIDENCE; INFANT; INFANT, NEWBORN; LEVODOPA; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; PREVALENCE; RISK FACTORS; WHOOPING COUGH;

EID: 0030443021     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/25.6.1301     Document Type: Article

References (61)

1. Gibb W R, Lees A J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.
2. Riederer P, Wuketich S. Time course of nigro-striatal degeneration in Parkinson's Disease. J Neurol Transm 1976; 38: 277-301.
3. Schoenberg B S. Environmental risk factors for Parkinson's disease: The epidemiologic evidence. Can J Neurol Sci 1987; 14: 407-13.
4. de Pedro-Cuesta J, Stawiarz L. Evaluation of how age modifies the risk for Parkinson's disease, based on stratified comparisons of descriptive data. Acta Neurol Scand 1991; 84: 295-302.
5. de Pedro-Cuesta J, Stawiarz L. Parkinson's Disease incidence: magnitude, comparability, time trends. Acta Neurol Scand 1991; 84: 382-88.
6. Gudmundsson K R A. A clinical survey of Parkinsonism in Iceland. Acta Neurol Scand 1967; 43: 9-61.
7. de Pedro-Cuesta J. Parkinson's Disease occurrence in Europe. Acta Neurol Scand 1991; 84: 357-65.
8. Tanner C M. Epidemiology of Parkinson's Disease. In: Cederbaum J M, Gaucher S T (eds), Parkinson's Disease, Neurologic Clinics. Philadelphia: W B Saunders, 1992, pp. 317-30.
9. Koller W, Vetere-Overfield B, Gray C et al. Environmental risk factors in Parkinson's Disease. Neurology 1990; 40: 1218-21.
10. Duvoisin R C, Johnson W G. Hereditary Lewy-body parkinsonism and evidence for a genetic etiology of Parkinson's Disease. Brain Pathol 1992; 2: 309-20.
11. Armstrong M, Daly A K, Cholerton S, Bateman D N, Idle J R. Mutant debrisoquine hydroxylation genes in Parkinson's Disease. Lancet 1992; 339: 1017-18.
12. Smith C A D, Gough A C, Leigh P N et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's Disease. Lancet 1992; 339: 1375-77.
13. Plante-Bordeneuve INITIAL, Davis M B, Maraganore D M, Marsden C D, Harding A E. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatr 1994; 57: 911-13.
14. de Pedro-Cuesta J. Studies on the prevalence of Paralysis Agitans by tracer methodology. Acta Neurol Scand 1987; 75(Suppl.): 6-106.
15. de Pedro-Cuesta J, Petersen I, Vassilopoulos F, Micheli F, Garcia-Iñesta A. Epidemiological assessment of levodopa use by populations. Acta Neurol Scand 1991; 83: 328-35.
16. de Pedro-Cuesta J. Risk factors of Parkinson's Disease. In: Vuylsteek K and Hallen M (eds). Epidemiology. Amsterdam: IOS Press, 1994, pp. 182-211.
17. de Pedro-Cuesta J, Wermuth L, Abraira V, Stawiarz L. Levodopa use in Denmark: high levels in Greenland and the Faroe Islands. Acta Neurol Scand 1995; 91: 89-97.
18. de Pedro-Cuesta J, Petersen I J, Stawiarz L et al. High levodopa use in periodically time-clustered, Icelandic birth cohorts. A vestige of parkinsonism etiology. Acta Neurol Scand 1995; 91: 79-88.
19. Schleissner P A. Island undersögt fra et laegevidenskabeligt synspunkt. Copenhagen 1849, pp. 65-68.
20. Del Kongelige Sundhedskollegium's Aarsberetning. Avsnitet Island. Copenhagen: 1852-1910.
21. Reports on the Health of People in Iceland, from 1881 onwards. Reykjavik: Surgeon General's Office, 1961.
22. Cliff A D, Haggett P, Ord J K, Versey, G R. In: Spatial Diffusion. A historical geography of epidemics in an island community. Cambridge: Cambridge University Press, 1981, pp. 192-93.
23. Andersson R M, May R M. Age-related changes in the rate of disease transmission: implications for design of vaccination programmes. J Hyg Camb 1985; 94: 365-436.
24. Christie A B. Whooping cough. In: Infectious diseases: Epidemiology and clinical practice. Fourth Edition. Vol 2. Edinburgh: Churchill Livingstone, 1987, pp. 927-58.
25. Rajput A H, Offord K P, Beard A M, Kurland L T. Epidemiology of Parkinsonism: Incidence, classification and mortality. Ann Neurol 1984; 16: 278-82.
26. Parati E A, Fetoni V, Geminiani G C et al. Response to L-dopa in multiple system atrophy. Clin Neuropharmacol 1993; 16: 139-44.
27. Andersson R M, May R M. Vaccination and herd immunity to infectious diseases. Nature 1985; 318: 323-29.
28. Baron J A. Cigarette smoking and Parkinson's Disease. Neurology 1986; 36: 1490-96.
29. Jansson A M. Protective actions of nicotine on lesioned nigrostriatal dopamine systems. PhD Thesis. Stockholm 1991.
30. Riggs J E. Cigarette smoking and Parkinson disease: The illusion of a neuroprotective effect. Clin Neuropharmacol 1992; 15: 88-99.
31. Semchuk K M, Love E J, Lee R G. Parkinson's disease and exposure to rural environmental factors: a population-based case control study. Can J Neurol Sci 1991; 18: 279-86.
32. Tanner C M, Chen B, Wang W et al. Environmental factors and Parkinson's Disease: a case control study in China. Neurology 1989; 39: 660-64.
33. Rajput A H, Uitti R J, Stern W, Lavertry W. Early-onset Parkinson's disease in Saskatchewan - Environmental considerations for etiology. Can J Neurol Sci 1986; 13: 312-16.
34. Ho S C, Woo J, Lee C M. Epidemiologic study of Parkinson's disease in Hong Kong. Neurology 1989; 390: 1314-18.
35. Wong G F, Gray C S, Hassanein R S, Koller W C. Environmental risk factors in siblings with Parkinson's disease. Arch Neurol 1991; 48: 287-89.
36. Morano A, Jiménez-Jiménez F J, Molina J A, Antolín M A. Risk factors for Parkinson's Disease: case-control study in the province of Cáceres, Spain. Acta Neurol Scand 1994; 89: 164-70.
37. Jiménez-Jiménez F J, Mateo D, Giménez-Roldán S. Exposure to well-water and pesticides in Parkinson's disease: a case-control study in the Madrid Area. Mov Disorders 1992; 7: 149-52.
38. Jansson B, Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol 1985; 17: 505-09.
39. Marmot M G. Mortality and Parkinson's disease. In: Rose F C, Capildeo R (eds). Research Progress in Parkinson's disease. Tunbridge Wells: Pitman Medical, 1981.
40. Sasco A J, Paffenbarger R S. Measles infection and Parkinson's disease. Am J Epidemiol 1985; 122: 1017-31.
41. Nasca Ph C, Burnett W S, Greenwald P, Brennan K, Wolfgang P, Carlton K. Population density as an indicator of urban-rural differences in cancer incidence, upstate New York 1968-1972. Am J Epidemiol 1980; 112: 362-75.
42. Gordon J E, Hood R I. Whooping cough and its epidemiological anomalies. Am J Med Sci 1951; 222: 333-61.
43. Khlat M, Khoury M. Inbreeding and diseases: demographic, genetic, and epidemiologic perspectives. Epidemiol Rew 1991; 13: 28-41.
44. Rosswell E, Rocca W A, Ince S E. Parkinson's Disease: evidence against a toxic aetiology and for an alternative theory. In: Markey P S (ed.) MPTP: A neurotoxin producing a parkinsonian syndrome. Academic Press. 1986, pp. 355-67.
45. Fishman P S, Gass J S, Swoveland P T, Lavi E, Highkin M K and Weiss S R. Infection of the basal ganglia by a murine coronavirus. Science 1985; 229: 877-79.
46. Mohammed A K, Magnusson O, Maehlen J et al. Behavioural deficits and serotonin depletion in adult rats after transient infant nasal viral infection. Neuroscience 1990; 35: 355-63.
47. Andersson T, Schultzberg M, Schwarcz R, Löve A, Wickman C, Kristensson K. NMDA-receptor antagonist prevents measles virus-induced neurodegeneration. Eur J Neurosci 1991; 3: 61-77.
48. Kohbata S, Beaman B L. L-Dopa-responsive movement disorder caused by Nocardia asteroides localized in the brains of mice. Infect Immun 1991; 59: 181-91.
49. Krantz T, Taranger J, Trollfors B. Estimating incidence of wooping cough over time - a cross-sectional recall study of four Swedish birth cohorts. Int J Epidemiol 1989; 18: 901-05.
50. Pittman M. Neurotoxicity of Bordetella Pertussis: Neurotoxicology 1986; 7: 53.
51. Boyajian C L, Bickford-Wimer P, Kim M B, Freedman R, Cooper D M. Pertussis toxin lesioning of the nucleus caudate-putamen attenuates adenylcyclase inhibition and alters neuronal electrophysiological activity. Brain Res 1989; 495: 66-74.
52. Fujita N, Nakahiro M, Fukuchi I, Saito K, Yoshida H. Effects of pertussis toxin on D2-dopamine receptor in rat striatum. Brain Res 1985; 333: 231-36.
53. Nomura Y, Arima T, Swgawa T. Influences of pertussis toxin, guanine nucleotides and forskolin on adenylate cyclase in striatal membranes of infant, adult and senescent rats. Int J Dev Neurosci 1987; 5: 271-79.
54. Rodier P M. Time of exposure and time of testing in developmental neurotoxicology. Neurotoxicology 1986; 7: 69-76.
55. Sato I, Sato H. Animal models of pertussis. In: Wardlaw A C, Parton R (eds). Pathogenesis and immunity in pertussis. Chichester: John Wiley, 1988, pp. 309-24.
56. +: the effects of aging. Life Sci 1987; 40: 749-54.
57. Ricaurte G A, DeLanney L E, Irwin I, Langston J W. Older dopaminergic neurons do nol recover from the effects of MPTP. Neuropharm 1987; 26: 97-99.
58. Pileblad E, Carlsson A. Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain. Neuropharmachol 1985; 24: 689-92.
59. Hyman C, Hofer M, Barde YA et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991; 350: 230-32.
60. Herrero M T, Hirsch E C, Kastner A et al. Appearance of neuromelanin with aging in catecholaminergic neurons of the brain-stem in macaca fascicularis. 10th International Symposium on Parkinson's Disease, Abstracts book, Tokyo, 1991, pp. 228.
61. Bossi S R, Simpson J R, Isacson O. Age dependence of striatal neuronal death caused by mitochondrial disfunction. Neuroreport 1993; 4: 73-76.